- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, April 12, 2019
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
The National Pharmaceutical Council’s Monday CER Daily Newsfeed included The American Journal of Managed Care® (AJMC®)'s coverage of the 2019 Community Oncology Conference. The article, “Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations,” covered a session that found while healthcare experts may agree that the shift from volume to value is well under way, the definition of value has a different answer depending who you ask. Tuesday’s newsfeed included an AJMC® interview with Daniel Ontaneda, MD, a neurologist at the Cleveland Clinic. During the interview, Ontaneda explained that there are 2 approaches for treating multiple sclerosis, and the DELIVER-MS study is the first to see which approach works better.
DocWire News’ article on generic drugs included the AJMC® published study “Consumer Attitudes and Factors Related to Prescription Switching Decisions in Multitier Copayment Drug Benefit Plans,” which surveyed patients and found that most respondents did not believe that formulary drugs were safer or more effective than nonformulary drugs, but 39.7% believed formulary drugs were relatively less expensive. Most patients indicated that they were willing to consider switching from a nonformulary drug to a formulary drug for a lower copayment.
Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Oncology Onward: A Conversation With Dr Debra Patt of Texas Oncology
August 1st 2023Debra Patt, MD, PhD, MBA, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for episode 2 of our newest podcast, "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care."
Listen
HMO and EPO Insurance Plans More Likely to Promote Use of Biosimilars
November 21st 2023Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Read More
